Today’s Stock Market in 2-Minutes
November 11, 2026
November 11, 2026
November 11, 2026
November 11, 2026
November 11, 2026
Watch the replay of Axe Compute's Second Quarter 2026 earnings conference call, originally held live on Monday, August 17, 2026 at 8:30 a.m. Eastern Time. Christopher Miglino, Chief Executive Officer; Kyle Okamoto, President; and Jeremy Yaukey-Witter, Chief Financial Officer, review the Company's Q2 2026 financial results, recent business developments, and priorities for the second half of 2026. Key highlights discussed on the call: Revenue grew more than 90x sequentially in the Company's first full quarter of compute operations Customer prepayments grew from $0.8 million to $60.8 million, with $17.4 million in operating cash flow in the first half of 2026 The $260 million dedicated cluster of 2,304 NVIDIA B300 GPUs progressed through build, targeted for Q3 2026 go-live Total 2026 signed contracted value now exceeds $3 billion Read the full press release and financial statements on Axe Compute's investor website.
August 17, 2026PALO ALTO, Calif., Aug. 15, 2024 /PRNewswire/ — Mega Matrix Corp. (“MPU” or the “Company”) (NYSE American: MPU), today announced that it launched its Japanese-language short drama “ドS社長と死にゆく奥様の百日戦争” on August 13th at FlexTV. The intense emotional confrontations in the drama are like sharp lancet blades, precisely dissecting the dark sides of the characters’ inner selves. This compels the audience […]
August 15, 2024
PLYMOUTH MEETING, Pa., Nov. 11, 2026 /PRNewswire/ — INOVIO (NASDAQ: INO), a commercial-stage biotechnology company focused on developing DNA medicines to help treat and protect people from HPV-related diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Jefferies Global Healthcare Conference in London Date: Wednesday, November 18 Time: 12:00 p.m. EST / 5:00 p.m. GMT Format: Presentation […]
November 11, 2026
Celairis receives exclusive rights to commercialize OCU400, Ocugen’s investigational modifier gene therapy for retinitis pigmentosa (RP), in Australia, New Zealand, and member states of the Association of Southeast Asian Nations (ASEAN) markets Expands access to a potential one-time treatment gene therapy for RP across a region with an estimated 725 million people, following potential OCU400 […]
November 10, 2026
Genprex Senior Director of Quality Control & Product Development to Present Insights from Parallel AAV and Lipid-Based Development Programs Presentation to Highlight Drug Development, Manufacturing and Optimization Considerations for Diabetes Gene Therapy AUSTIN, Texas — (Nov. 11, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage biotechnology company developing gene therapies designed to restore tumor-suppressor function […]
November 11, 2026
November 11, 2026
November 11, 2026
November 11, 2026
November 11, 2026
November 11, 2026
November 11, 2026
November 11, 2026
November 11, 2026